Thierry Horner

1.2k total citations
20 papers, 674 citations indexed

About

Thierry Horner is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Thierry Horner has authored 20 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 5 papers in Pathology and Forensic Medicine and 3 papers in Genetics. Recurrent topics in Thierry Horner's work include Protein Degradation and Inhibitors (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Cancer-related gene regulation (4 papers). Thierry Horner is often cited by papers focused on Protein Degradation and Inhibitors (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Cancer-related gene regulation (4 papers). Thierry Horner collaborates with scholars based in United States, United Kingdom and France. Thierry Horner's co-authors include Phil Oh, Jan E. Schnitzer, Rick A. Rogers, Jun Liu, Shoji Osawa, Ellen R. Weiss, Aimin Li, Cheryl M. Craft, Arindam Dhar and Michael D. Schaller and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Thierry Horner

19 papers receiving 663 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thierry Horner United States	11	536	224	105	74	54	20	674
Michelle A. Booden United States	10	555 1.0×	189 0.8×	53 0.5×	64 0.9×	93 1.7×	11	696
Mohini Lutchman United States	14	325 0.6×	252 1.1×	77 0.7×	105 1.4×	56 1.0×	22	733
Craig M. Forester United States	11	603 1.1×	204 0.9×	94 0.9×	38 0.5×	97 1.8×	15	800
Mark Kloos United States	8	304 0.6×	176 0.8×	283 2.7×	43 0.6×	57 1.1×	14	736
Breann L. Wolfe United States	5	411 0.8×	168 0.8×	119 1.1×	44 0.6×	54 1.0×	6	654
Borislav Stoyanov Germany	6	582 1.1×	152 0.7×	52 0.5×	76 1.0×	101 1.9×	8	808
Marguerite Joly United States	12	670 1.3×	412 1.8×	99 0.9×	113 1.5×	74 1.4×	14	992
Padmaja Kunapuli United States	12	386 0.7×	92 0.4×	149 1.4×	30 0.4×	54 1.0×	14	545
S Ahern United States	7	307 0.6×	154 0.7×	100 1.0×	41 0.6×	26 0.5×	8	558
Michela Mazzocco Italy	10	516 1.0×	304 1.4×	57 0.5×	78 1.1×	21 0.4×	14	668

Countries citing papers authored by Thierry Horner

Since Specialization

Citations

This map shows the geographic impact of Thierry Horner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Horner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Horner more than expected).

Fields of papers citing papers by Thierry Horner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thierry Horner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Horner. The network helps show where Thierry Horner may publish in the future.

Co-authorship network of co-authors of Thierry Horner

This figure shows the co-authorship network connecting the top 25 collaborators of Thierry Horner. A scholar is included among the top collaborators of Thierry Horner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thierry Horner. Thierry Horner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cescon, David W., John Hilton, Serafín Morales, et al.. (2023). A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 30(2). 334–343. 10 indexed citations

Horner, Thierry, et al.. (2021). Species-Specific Differences in Expression of G-Protein-Coupled Receptor Kinase (GRK) 7 and GRK1 in Mammalian Cone Photoreceptor Cells: Implications for Cone Cell Phototransduction. UNC Libraries.

Cousin, Sophie, Jean‐Yves Blay, Irene García, et al.. (2020). BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.. Journal of Clinical Oncology. 38(15_suppl). 3618–3618. 5 indexed citations

Yap, Timothy A., Jane N. Winter, Lisa Giulino‐Roth, et al.. (2019). Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical Cancer Research. 25(24). 7331–7339. 128 indexed citations

Zelenetz, Andrew D., Leslie Popplewell, Ariela Noy, et al.. (2019). Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 20(11). 749–756.e1. 2 indexed citations

Gadgeel, Shirish M., Vicki L. Keedy, S. Taylor, et al.. (2017). Abstract CT104: A first-in-human phase I dose escalation study of BET inhibitor GSK2820151 in patients with advanced or recurrent solid tumors cancers. Cancer Research. 77(13_Supplement). CT104–CT104. 3 indexed citations

Rasco, Drew, Anthony W. Tolcher, Lillian L. Siu, et al.. (2017). Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma. Cancer Research. 77(13_Supplement). CT038–CT038. 12 indexed citations

Leonard, John P., Stephanie A. Gregory, Hedy Smith, et al.. (2016). CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 16(4). 191–196. 2 indexed citations

O’Dwyer, Peter J., Sarina A. Piha‐Paul, Christopher A. French, et al.. (2016). Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers. Cancer Research. 76(14_Supplement). CT014–CT014. 26 indexed citations

10.

Yap, Timothy A., Jane N. Winter, John P. Leonard, et al.. (2016). A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). Blood. 128(22). 4203–4203. 16 indexed citations

11.

Yap, Timothy A., Peter Johnson, Jane N. Winter, et al.. (2016). A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor.. Journal of Clinical Oncology. 34(15_suppl). TPS2595–TPS2595. 11 indexed citations

12.

Borthakur, Gautam, Mark A. Dawson, Eytan M. Stein, et al.. (2016). A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies. Blood. 128(22). 5223–5223. 8 indexed citations

13.

Wahl, Richard L., Thierry Horner, Thomas S. Lin, & Mark Kaminski. (2015). Observational Retrospective Study of Altered Biodistribution of Tositumomab and ¹³¹I-Tositumomab. Journal of Nuclear Medicine. 56(11). 1800–1803. 2 indexed citations

14.

Oh, Phil, Thierry Horner, Halina Witkiewicz, & Jan E. Schnitzer. (2012). Endothelin Induces Rapid, Dynamin-mediated Budding of Endothelial Caveolae Rich in ET-B. Journal of Biological Chemistry. 287(21). 17353–17362. 23 indexed citations

15.

Kaminski, Mark, Andrew D. Zelenetz, Oliver W. Press, et al.. (2010). Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas. Blood. 116(21). 3960–3960. 2 indexed citations

16.

Horner, Thierry, Wi S. Lai, Deborah J. Stumpo, & Perry J. Blackshear. (2009). Stimulation of Polo-Like Kinase 3 mRNA Decay by Tristetraprolin. Molecular and Cellular Biology. 29(8). 1999–2010. 30 indexed citations

17.

Kaminski, Mark, Melissa Tuck, Judith Estes, et al.. (2009). Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results.. Blood. 114(22). 3759–3759. 19 indexed citations

18.

Horner, Thierry, Shoji Osawa, Michael D. Schaller, & Ellen R. Weiss. (2005). Phosphorylation of GRK1 and GRK7 by cAMP-dependent Protein Kinase Attenuates Their Enzymatic Activities. Journal of Biological Chemistry. 280(31). 28241–28250. 43 indexed citations

19.

Weiss, Ellen R., et al.. (2001). Species-Specific Differences in Expression of G-Protein-Coupled Receptor Kinase (GRK) 7 and GRK1 in Mammalian Cone Photoreceptor Cells: Implications for Cone Cell Phototransduction. Journal of Neuroscience. 21(23). 9175–9184. 101 indexed citations

20.

Liu, Jun, Phil Oh, Thierry Horner, Rick A. Rogers, & Jan E. Schnitzer. (1997). Organized Endothelial Cell Surface Signal Transduction in Caveolae Distinct from Glycosylphosphatidylinositol-anchored Protein Microdomains. Journal of Biological Chemistry. 272(11). 7211–7222. 231 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact